Aquestive Therapeutics (AQST) risk factors

65 risks, 10 new, 10 dropped, 11 reworded since the prior year. New geopolitical risks highlight potential supply chain disruptions from baseline tariffs on imports from China, Canada, and Mexico. The company added operational and regulatory risks concerning its deployment of artificial intelligence across R&D and manufacturing. Intellectual property and clinical trial progression risks remain central to regulatory approvals for product candidates like Anaphylm.

65 risks. Company faces substantial accumulated deficits totaling $363.2 million and relies heavily on a single customer and licensed products like Sympazan, Suboxone, and Azstarys. Operations depend on complex manufacturing processes with limited suppliers for thin film foil and API. Capital needs require ongoing financing and debt management, including $45.0 million in 13.5% Notes.